Texas researchers sits at the center of this dementia and brain health question.

Texas researchers are developing multiple promising new approaches to prevent Alzheimer’s disease, moving beyond traditional treatment methods to address root causes like viral infections, inflammation, and breakdown of brain protective mechanisms. These advances represent a significant shift in how scientists understand Alzheimer’s risk and what can be done to intervene early, before symptoms emerge. Texas has emerged as a national hub for this preventive research, with major funding from both federal grants and a landmark state initiative approved by voters in 2025. This article covers the cutting-edge prevention strategies being pursued at Texas’s leading research institutions, the evidence supporting each approach, state-level investments that are accelerating this work, and what these findings mean for people concerned about dementia risk.

How Are Texas Researchers Approaching Alzheimer’s Prevention Differently?
The Anti-Inflammatory and Cannabis-Based Prevention Strategy
Understanding Brain Support Cells as a Prevention Target
Texas State Funding and the Dementia Prevention Institute
Important Limitations and Uncertainties in Current Research
How Prevention-Focused Research Differs from Current Alzheimer’s Treatments
What Comes Next in Texas Alzheimer’s Prevention Research
Conclusion

How Are Texas Researchers Approaching Alzheimer’s Prevention Differently?

Rather than waiting for Alzheimer’s to develop and then treating its symptoms, Texas researchers are working upstream—investigating what causes the disease in the first place and how to stop it before it starts. One major focus is viral infections. Dr. Ryan S.

Dhindsa at Texas Children’s Duncan Neurological Research Institute and Baylor College of Medicine received a $2 million grant from the American brain Foundation’s Cure One, Cure Many award to investigate how viruses may contribute to Alzheimer’s disease. His team will analyze genetic and health data from over 1 million individuals to identify patterns linking viral exposures, immune system responses, and Alzheimer’s development. This viral infection angle is significant because it suggests that some cases of Alzheimer’s might be preventable through antiviral treatments or vaccines—interventions that target a specific trigger rather than trying to reverse years of brain damage. The research focuses on finding those connections in large datasets before traditional clinical symptoms appear, making early intervention possible. For someone with a family history of Alzheimer’s or a history of serious infections, this approach offers a concrete pathway: identifying which viral exposures increase risk and then potentially preventing or treating them with greater urgency.

How Are Texas Researchers Approaching Alzheimer's Prevention Differently?

The Anti-Inflammatory and Cannabis-Based Prevention Strategy

Another major approach emerging from Texas research involves controlling inflammation, which is increasingly recognized as a driver of brain aging and Alzheimer’s development. Researchers at The University of Texas at San Antonio, led by Professor Chu Chen, published findings in December 2025 showing that a low-dose THC extract paired with celecoxib—a selective anti-inflammatory drug—reduced neuroinflammation and supported brain health in their study models. This combination approach is noteworthy because it attempts to capture benefits of cannabis compounds while minimizing potential negative effects through the addition of a targeted anti-inflammatory.

The celecoxib component is important to understand: it’s a selective COX-2 inhibitor, meaning it targets inflammation pathways while being more selective than broad-spectrum anti-inflammatory approaches. This specificity matters because overly broad inflammation suppression can also interfere with beneficial immune functions. However, if someone is considering this approach, they should be aware that both THC and celecoxib carry their own risk profiles—celecoxib has gastrointestinal and cardiovascular considerations, and THC effects vary by individual. The research is promising, but translation to clinical practice will require careful trials and patient selection.

Understanding Brain Support Cells as a Prevention Target

Beyond inflammation and infection, Texas A&M University researcher Dr. Jianrong Li received a $2.17 million grant from the National Institute on Aging to examine how the brain’s support cells protect nerve cells and what goes wrong in early Alzheimer’s disease. These support cells—primarily glial cells like astrocytes and microglia—essentially act as the brain’s immune system and maintenance crew. When they function properly, they clear debris, support neuron health, and maintain the brain’s environment.

But in Alzheimer’s disease, this protective function breaks down. Li’s research focuses on the earliest stages of this breakdown, before neurons die and cognitive decline becomes noticeable. This approach is preventive in the truest sense: if scientists can identify why support cells fail and restore their protective function early, they might prevent the cascade of damage that leads to dementia. For someone at genetic risk for Alzheimer’s or showing early cognitive changes, this research suggests that understanding personal brain cell function through advanced imaging or biomarkers could eventually guide preventive therapy directed at restoring cellular support systems rather than just suppressing symptoms.

Understanding Brain Support Cells as a Prevention Target

Texas State Funding and the Dementia Prevention Institute

In November 2025, Texas voters approved Proposition 14, authorizing $3 billion for the Dementia Prevention and Research Institute of Texas (DPRIT), with up to $300 million available annually after the initial allocation. This is the largest state-funded dementia research initiative in the nation, reflecting recognition at the policy level that Alzheimer’s prevention is a public health priority deserving major investment. This funding accelerates all the research described above and creates new opportunities for clinical trials and translation of laboratory findings into patient treatments.

The scale of this investment matters. $3 billion can fund not just laboratory research but also large clinical trials, training for new researchers, and infrastructure for biomarker discovery. However, funding alone doesn’t guarantee success—the quality of research design, the ability to recruit diverse participant populations, and the willingness to pursue approaches that don’t pan out are equally critical. Texas’s investment positions the state to lead nationally on prevention, but that leadership will depend on how effectively researchers use these resources to move discoveries from bench to bedside.

Important Limitations and Uncertainties in Current Research

While these developments are encouraging, it’s critical to recognize what remains unknown. The viral infection research, for example, is correlational at this stage—identifying that people with certain viral exposures have higher Alzheimer’s risk doesn’t automatically mean preventing those infections will prevent the disease. The mechanisms could be more complex, involving genetic susceptibility, timing of infection, or interactions with other risk factors. Additionally, not everyone exposed to these viruses develops Alzheimer’s, suggesting other protective factors play important roles.

The THC and celecoxib combination shows promise in laboratory and early-stage studies, but translation to large-scale human trials hasn’t yet occurred. Cannabis research remains federally complicated in many contexts, which can slow clinical development even when preliminary data looks promising. For the brain support cell research, Dr. Li’s work is foundational—understanding how cells function and what goes wrong is necessary, but developing drugs or therapies that can safely restore those functions in human brains is a longer journey. Anyone considering lifestyle changes or treatment based on this research should wait for clinical trial results rather than assuming these approaches are ready for routine use.

Important Limitations and Uncertainties in Current Research

How Prevention-Focused Research Differs from Current Alzheimer’s Treatments

Most current Alzheimer’s medications target symptoms in people who already have cognitive decline—they attempt to slow progression, not prevent disease from developing in the first place. The Texas research approaches are fundamentally different: they’re attempting to intervene in asymptomatic people based on risk factors like viral exposure history, genetic markers, or brain changes visible only on advanced imaging. This preventive focus is more similar to how medicine approaches heart disease (statins for high-risk people, blood pressure control) or cancer screening, but it requires identifying who is truly at high risk before disease manifests.

This shift has practical implications. It means future Alzheimer’s prevention might involve blood tests to check for viral antibodies or brain inflammation markers, genetic counseling for people with family history, or regular brain imaging for at-risk individuals—not just waiting until someone forgets their address. It also means that prevention strategies might work differently for different people based on their underlying risk profile: one person might benefit from antiviral surveillance, another from anti-inflammatory approaches, a third from interventions targeting brain cell support.

What Comes Next in Texas Alzheimer’s Prevention Research

The immediate timeline for these approaches varies significantly. The viral infection research under Dr. Dhindsa is in data analysis phase now, with results likely within the next 2-3 years that could identify specific viral candidates for further investigation. The THC-celecoxib study has already published, but moving to clinical trials in humans would be the next phase. Dr.

Li’s brain cell research is foundational and will likely require 5-10 years before therapeutic candidates emerge. The $3 billion Proposition 14 funding creates opportunity to accelerate all of these timelines through new clinical trials and research support. Looking forward, the Texas research landscape suggests that Alzheimer’s prevention in the next 10 years will likely involve personalized risk assessment—knowing your own genetic risk, viral exposure history, inflammatory markers, and brain imaging findings—followed by targeted interventions matched to your specific risk profile. Texas’s concentration of research efforts and funding positions the state to pioneer this approach and potentially develop preventive strategies that could reduce Alzheimer’s incidence at a population level. The field is moving from “one treatment fits all” toward precision prevention.

Conclusion

Texas researchers are developing multiple complementary approaches to prevent Alzheimer’s disease by targeting root causes: viral infections, brain inflammation, and breakdown of protective brain cell functions. These advances, supported by major federal grants and the nation’s largest state-funded dementia research initiative, represent a fundamental shift toward prevention rather than treatment of advanced disease. The research is solid and the investment is serious, but it’s important to recognize that most approaches are still in research or early clinical phases.

For people concerned about Alzheimer’s risk, the immediate steps remain the evidence-based ones: managing cardiovascular health, staying cognitively active, maintaining social engagement, and getting adequate sleep. Following developments in Texas and national Alzheimer’s research over the next 3-5 years will reveal which preventive approaches move from laboratory findings to clinical reality. Staying informed about this research, discussing risk factors with your doctor, and participating in clinical trials if eligible are concrete ways to contribute to and benefit from these advances.